CARDIOGRAFIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOGRAFIN is an injectable diagnostic agent developed by Bracco, approved in 1958 for cardiac imaging and visualization. The product is used to enhance radiographic visualization of cardiac structures and blood flow. It functions as a contrast medium to improve imaging quality during cardiovascular diagnostic procedures.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely optimizing market position while preparing for generic erosion and potential portfolio transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CARDIOGRAFIN offers limited external job market activity (0 linked positions), suggesting this is a maintenance-mode product with stable but declining career expansion potential. Roles focus on defending market share and managing the LOE transition rather than growth innovation.
Brand ManagerProduct Manager
Worked on CARDIOGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.